- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial, Adaptive Platform Trial, Treatment
- Objective: To evaluate the effectiveness of an integrated care pathway in improving fatigue and physical, psychological, and functional outcomes in adults with Long COVID, and to assess, through an embedded Phase III open-label platform randomised drug trial, the efficacy of candidate therapies such as rivaroxaban, colchicine, and famotidine/loratadine compared with no drug treatment
- Number of participants enrolled: Enrollment ongoing
- Study enrolling from
Study Data
- Adults
- General population
- Community
- SARS-CoV-2
- Post-COVID-19
- Antihistamines
- Colchicine
- Rivaroxaban
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to